Fresenius Kabi Increases Stake in Dabur Pharma

Fresenius Kabi (Bad Homburg, Germany), a unit of health care group Fresenius SE, says it has completed the acquisition of Indian generics and active pharmaceutical ingredients (API) firm Dabur Pharma (New Delhi), with the purchase of a further 17.6% stake in the firm. Fresenius Kabi acquired 73.3% stake in Dabur Pharma in April for about €139 million ($224 million) (CW, April 28, p. 29). Relevant approvals required under the Indian law have also been secured, Fresenius Kabi says. Dabur Pharma is a manufacturer and supplier of generic drugs and APIs to...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers